Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

Anoro Ellipta is a brand-name prescription medication to manage chronic obstructive pulmonary disease (COPD) symptoms in adults. Common side effects of Anoro Ellipta are generally mild, but serious ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...

Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...

GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...